OBJECTIVE: The adjuvant treatment of high-risk @entity1204 (HREC) remains controversial. This prospective phase-II clinical trial was conducted to evaluate the adjuvant concurrent chemoradiotherapy followed by chemotherapy in @entity1 with HREC. METHODS: Altogether 122 @entity1 were enrolled between January 2007 and January 2013, in which 112 were analyzable. The inclusion criteria included @entity1204 of histological grade 3 and with greater than 50% myometrial invasion, cervical stromal invasion, pelvic and/or para-aortic lymph node @entity3 ; non- @entity1204 ; no @entity66 and distant @entity3 . Pelvic radiation was administered with @entity900 on days 1 and 28. Para-aortic radiation was administered with confirmed para-aortic lymph node @entity3 , and vaginal afterloading brachytherapy with cervical stromal invasion after total hysterectomy. Four courses of @entity1311 and @entity3003 (PC) or @entity900 , @entity786 and @entity1259 (CEP) were administered at three-week interval after radiation. RESULTS: Ninety-six @entity1 (85.7%) completed the planned treatment. Treatment discontinuation was the result of @entity137 (5/112, 4.5%), disease progression (8/112, 7.1%), and @entity1 refusal (3/112, 2.7%). There was no life-threatening @entity137 . Twenty-five (22.3%) @entity1 recurred, in which 4 cases recurred in the field of radiation, and 13 (11.6%) @entity1 died of @entity1204 during follow-up. The estimated five-year progression-free survival and overall survival were 73% and 84%, respectively. Adverse effects were less common in @entity1 who received PC than CEP (p=0.001). CONCLUSIONS: This regimen demonstrated acceptable @entity137 and good survival outcomes despite a preponderance (62.5%) of late stage disease. PC showed less adverse effects than CEP. A well designed randomized trial is under development. CLINICAL TRIAL ID: https://clinicaltrials.gov/: 070148-7.

Adjuvant concurrent chemoradiation followed by chemotherapy for high-risk XXXX .

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer', 'endometrioid endometrial cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']
@entity1204 :: (MESH:D016889,Disease) :: ['endometrial cancer']
